Interference of maternal antibodies with the immune response of foals after vaccination against equine influenza.
The purpose of the study was twofold. First, using two groups of 22 foals each, we investigated the extent to which maternal antibodies interfere with the humoral response against equine influenza. The foals were born to mares that had been vaccinated twice yearly against influenza since 1982. Foals of group I were vaccinated three times at early ages (12, 16, and 32 weeks of age), and foals of group II were likewise vaccinated but a later ages (24, 28, and 44 weeks of age). After the first and second vaccinations, neither group showed an increase in antibodies that inhibit haemagglutination. Group II foals, however, had a significantly stronger antibody response against nucleoprotein after the second vaccination than the foals of group I. After the third vaccination, group II foals had a significantly stronger and longer lasting antibody response against haemagglutinin than the foals of group I. However, the antibody response to nucleoprotein was comparable in both groups. Second, the foals of group II were studied to determine the persistence of maternal antibodies directed against a common nucleoprotein and the haemagglutinin of two strains of equine influenza A virus. Biological half-lives of 39, 32, and 33 days were calculated for maternal antibodies directed against haemagglutinin of strains H7N7 Prague and H3N8 Miami, and against the nucleoprotein respectively. Maternal antibody titres at the time of vaccination were closely related to the degree of interference with the immune response. Because even small amounts of maternal antibodies interfered with the efficacy of vaccination, we conclude that foals born to mares vaccinated more than once yearly against influenza virus should not be vaccinated before 24 weeks of age.
van Maanen
C
C
Central Veterinary Institute, Lelystad, The Netherlands.
Bruin
G
G
de Boer-Luijtze
E
E
Smolders
G
G
de Boer
G F
GF
D000367:Age Factors; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006207:Half-Life; D006385:Hemagglutination Inhibition Tests; D006389:Hemagglutinins, Viral / Q000276:immunology; D006736:Horses / Q000276:immunology*; D007112:Immunity, Maternally-Acquired; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins / Q000276:immunology; D011247:Pregnancy; D016601:RNA-Binding Proteins; D011897:Random Allocation; D012044:Regression Analysis; D014611:Vaccination / Q000662:veterinary; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014758:Viral Core Proteins / Q000276:immunology
D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; C048842:NP protein, Influenza A virus; D019590:Nucleocapsid Proteins; D009698:Nucleoproteins; D016601:RNA-Binding Proteins; D015164:Vaccines, Inactivated; D014758:Viral Core Proteins